https://www.selleckchem.com/pr....oducts/cirtuvivint.h
02) and increase in backfill score (p = 0.005) vs placebo, with no significant between-group differences for ankylosis (p = 0.46) or fat metaplasia (p = 0.17). At week 12, change in SPARCC MRI SI joint inflammation scores correlated positively with erosion scores but negatively with backfill scores. The significant changes in MRI structural lesions induced by filgotinib in the SI joint by week 12 demonstrate that tissue repair can be observed very soon after starting treatment with a JAK1 preferential inhibitor. This could have prog
Like
Comment
Share
